A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

NCT01047345 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

924

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancers
Vulvar Cancers
Vaginal Cancers
Genital Warts

Interventions

BIOLOGICAL: V503
BIOLOGICAL: Placebo to V503

Sponsor

Merck Sharp & Dohme LLC